In Search of Novel Means to Provoke Mild Mitochondrial Stress to Slow Aging

Key Takeaways

• Screened 770 FDA‑approved drugs for mitochondrial stress activation
• Terbinafine and miglustat extended C. elegans lifespan
• Both compounds trigger UPRmt and DAF‑16 insulin signaling
• They lack antibacterial activity, avoiding microbiome disruption
• Mitochondrial stress response also induced in human cell models

Pulse Analysis

Mild mitochondrial stress, or mitohormesis, has emerged as a compelling strategy to boost cellular maintenance pathways and slow age‑related decline. By modestly impairing mitochondrial function, cells up‑regulate quality‑control mechanisms such as the mitochondrial unfolded protein response (UPRmt), increase antioxidant production, and recalibrate metabolic signaling. This adaptive response mirrors the benefits seen with calorie restriction and intermittent fasting, yet offers a pharmacological route that can be precisely tuned.

In a recent open‑access study, scientists performed a high‑throughput screen of 770 FDA‑approved compounds using the nematode C. elegans as a model organism. Terbinafine, an antifungal, and miglustat, a sphingolipid‑reduction drug, emerged as the most robust activators of the mitochondrial stress response. Both agents extended worm lifespan and improved healthspan metrics by engaging the UPRmt and a DAF‑16‑dependent insulin/IGF‑1 signaling cascade, distinct from traditional pathway activation. Crucially, unlike doxycycline, these drugs lack antibacterial activity, sidestepping microbiome disruption and resistance concerns. Parallel assays demonstrated that human fibroblasts and neuronal cells also mounted a mitochondrial stress response when treated with the same compounds, underscoring translational relevance.

The findings position terbinafine and miglustat as promising candidates for repurposing into geroprotective therapies. By leveraging existing safety data, developers can accelerate clinical evaluation, potentially delivering a new class of age‑modulating drugs that improve metabolic health without the drawbacks of antibiotics. As the biotech industry intensifies its focus on senescence and mitochondrial dysfunction, such pharmacological mitohormesis agents could capture significant market share and reshape strategies for managing chronic, age‑linked diseases.